Perioperative chemotherapy and nivolumab in non-small cell lung cancer (NADIM): 5-year clinical outcomes from a multicenter, single-arm, phase 2 trial
Year: 2024
Type: article
Study design: Clinical Trial
Authors: Provencio, Mariano, Nadal, Ernest, Insa, Amelia, García Campelo, Rosario, Casal, Joaquín, Dómine, Manuel, Massuti, Bartomeu, Majem, Margarita, Rodríguez Abreu, Delvys, Martínez-Martí, Alex, Castro, Javier de, Gómez de Antonio, David, Macía, Ivan, Figueroa, Santiago, Fernández Vago, Luís, Calvo, Virginia, Palmero, Ramón, Sierra Rodero, Belén, Martínez-Toledo, Cristina, Molina-Alejandre, Marta, Serna-Blasco, Roberto, Romero, Atocha, Cruz-Bermúdez, Alberto
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: non-small cell lung cancer, perioperative immunotherapy, nivolumab, neoadjuvant chemotherapy, adjuvant immunotherapy, paclitaxel, carboplatin, stage IIIA lung cancer, progression-free survival, overall survival, long-term outcomes, immune-related adverse events, resectable lung cancer, immunotherapy toxicity
Open Access status: green
OpenAlex ID: W7042235390
